[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 1973

Ampicillin RashesCollaborative Study

Arch Dermatol. 1973;107(1):74-76. doi:10.1001/archderm.1973.01620160046013

In a clinical trial comparing two brands of ampicillin, similar proportions of patients developed dermatologic reactions with each product. This finding, taken in conjunction with epidemiologic data on other brands, suggests that there is no substantial difference with regard to cutaneous eruptions between the various commercially available brands of ampicillin. Current epidemiologic data suggest that the attributable risk for ampicillin rashes with all brands is about 9%. The morphologic characteristics of the ampicillin rashes were similar to those of drug eruptions in general.